The Pill That Outran Its Explanation
Metformin is taken by well over a hundred million people, and three serious labs now claim three different organs as its true target — a disagreement that is the honest state of the science, not a failure of it.
2026-08-05
Metformin is one of the most-prescribed drugs on Earth and has been in daily use for more than sixty years, yet there is still no settled answer to the simple question of where in the body it does its work. This episode lays out the three rival accounts — the classic liver story, a strong case for the gut, and a 2025 paper from Baylor arguing that a control point in the brain is necessary at low doses in mice. It separates what that new study actually shows, that removing one protein in one brain region silences the drug, from the headline that we have finally cracked metformin. The larger argument is that medicine licenses drugs on whether they work and are safe, not on whether we understand them, so mechanism routinely arrives after use, and sometimes never in full. Along the way it explains why very little of the drug reaching a very sensitive target can still matter, and why not knowing the mechanism carries a real cost.
Transcript
Follows the audio as it plays — tap any sentence to jump there.
Somewhere near you, probably within a short walk, someone is taking a small white pill with breakfast. It is called metformin.在离你不远的某个地方,也许步行几分钟就到,有人正就着早餐吃下一小片白色药丸。它叫二甲双胍。 On any list of the medicines the human race swallows most often, it would sit near the top.在人类服用最频繁的药物清单上,无论哪一份,它都会排在靠前的位置。 Well over a hundred million people take it, most for type 2 diabetes, some now in the quiet hope that it slows down aging.服用它的人远超一亿,多数是为了治疗 2 型糖尿病,如今也有一些人抱着它能延缓衰老的悄然期望在吃。 It is cheap, and it has been in daily use for more than sixty years. And here is the strange part.它很便宜,而且已经日常使用了六十多年。奇怪的地方就在这里。 Ask a room full of experts exactly how it works, and you will not get one answer. You will get an argument. That is the story tonight.去问一屋子专家它到底是怎么起作用的,你不会得到一个统一的答案。你会得到一场争论。这就是今晚要讲的故事。
Not really a new discovery, more an old and honest confusion that a paper from last year has sharpened rather than settled.这算不上什么新发现,更像是一桩由来已久、坦诚存在的困惑——去年的一篇论文让它变得更尖锐,而非把它解决了。 The headlines said we had finally cracked it.各种头条说我们终于把它弄清楚了。 What actually happened is more interesting, and it tells you something about how medicine really works, which is not the way the textbooks pretend.实际发生的事情要有意思得多,它会让你看到医学真正的运作方式,而那和教科书假装的样子并不一样。
Start with where the drug comes from, because the beginning already contains the lesson. Metformin descends from a plant.先从这种药的来源说起,因为开端本身就已经包含了教训。二甲双胍源自一种植物。 In medieval Europe people grew a herb called goat's rue, also known as French lilac.在中世纪的欧洲,人们种植一种叫山羊豆的草本植物,它也被称为法国紫丁香。 Farmers noticed it made cattle give more milk, and healers gave it to people with the thirst and frequent urination we now recognize as diabetes.农民注意到它能让牛产更多奶,医者则把它给那些有口渴和尿频症状的人——也就是我们如今认识的糖尿病。 In 1914 a French pharmacist pulled the active compound out of the plant. It lowered blood sugar. It was also too toxic to use.1914 年,一位法国药剂师从这种植物中提取出了活性化合物。它能降血糖,但毒性也太大,无法使用。 Chemists in the 1920s built a family of related molecules called biguanides, and one of them, metformin, was tried in people by a French physician named Jean Sterne in 1957, who gave it a hopeful name that translates roughly as glucose eater.20 世纪 20 年代的化学家构建出了一族相关分子,称为双胍类,其中之一就是二甲双胍。1957 年,一位名叫 Jean Sterne 的法国医生在人体上试用了它,并给它取了个满含希望的名字,大致可译为「吃葡萄糖的东西」。 Notice what did not happen in that sequence. Nobody understood the mechanism.注意这一连串过程中没有发生什么。没有人理解它的机制。 They had a plant that worked, then a molecule that worked, and the working came first. Understanding was supposed to catch up later.他们先有了一种有效的植物,再有了一种有效的分子,起效是第一位的。理解本应在之后才跟上。
It has been a long later. And metformin nearly did not survive to see it.这个「之后」等了很久。而二甲双胍差点没能活到那一天。 It had two chemical siblings, phenformin and buformin, sold at the same time.它有两个化学上的同胞——苯乙双胍和丁双胍,当时一同在售。 In the 1970s those two were found to cause a dangerous buildup of acid in the blood, a condition called lactic acidosis, and were pulled from the market in most countries.20 世纪 70 年代,人们发现这两种药会导致血液中危险的酸性物质堆积,一种叫乳酸酸中毒的状况,于是在多数国家被撤出市场。 Metformin causes the same problem, but far more rarely.二甲双胍也会引发同样的问题,但要罕见得多。 Very roughly, phenformin harmed about one patient in four thousand, metformin something closer to one in tens of thousands.非常粗略地说,苯乙双胍大约每四千名患者中伤害一人,二甲双胍则接近每几万人中才有一人。 That gap in the numbers is the whole reason one drug became a global staple and the other two became footnotes.数字上的这道差距,正是一种药成为全球主力、另外两种沦为脚注的全部原因。 It was a matter of degree, and metformin was nearly dragged down with its relatives.这是一个程度的问题,而二甲双胍差一点就被它的亲戚一起拖下水。 Instead it became the drug most doctors reach for first in type 2 diabetes.结果它反而成了多数医生治疗 2 型糖尿病时首先想到的药。
So we have a drug taken by a huge fraction of humanity, with a good record and a clear benefit.所以我们有了这样一种药:全人类中有很大一部分人在服用,记录良好,益处明确。 Now comes the question that should have a simple answer and does not. Where in the body does it actually act?现在轮到那个本该有简单答案、却偏偏没有的问题了。它在体内究竟作用于哪里?
The textbook answer, the one most people carry, is the liver.教科书上的答案,也是大多数人记住的那个,是肝脏。 Your liver makes glucose and releases it into the blood, and the story went that metformin tells the liver to make less, by switching on an energy sensor inside cells called AMPK.你的肝脏制造葡萄糖并把它释放进血液,而那套说法是:二甲双胍通过开启细胞内一种叫 AMPK 的能量感应器,告诉肝脏少造一点。 For years that was the settled picture. Then it started to wobble.多年来这都是既定的图景。然后它开始动摇。 Careful experiments showed you could lower blood sugar with metformin even when you blocked the supposed pathway, which is not what you would expect if that pathway were the whole story.严谨的实验显示,即便你阻断了那条据称的通路,二甲双胍仍能降低血糖——如果那条通路就是全部真相,这可不该发生。
Then a second camp made a strong case for a different organ entirely, the gut. When you swallow metformin, it does not spread evenly.接着第二个阵营为一个完全不同的器官——肠道——提出了有力的论据。当你吞下二甲双胍,它并不会均匀地散布开来。 It piles up in the intestine at concentrations far higher than it ever reaches in the blood. And here is the striking finding.它在肠道中的浓度远高于它在血液中所能达到的水平。而这里有一个引人注目的发现。 You can deliver metformin so that it acts only in the gut, without raising its level in the bloodstream at all, and blood sugar still falls.你可以让二甲双胍只在肠道中发挥作用,而完全不提升它在血液中的浓度,血糖仍然会下降。 The gut, in this account, changes how it handles glucose and signals onward to the liver. This camp has a neat bonus argument.按照这种说法,肠道改变了它处理葡萄糖的方式,并向下游的肝脏发出信号。这一派还有一个漂亮的附加论据。 Metformin's most famous side effect is that it upsets the stomach, especially at first.二甲双胍最出名的副作用是它会引起胃部不适,尤其是在刚开始服用时。 If the gut is where the drug is really working, that side effect is not a random nuisance. It is sitting right next to the mechanism.如果肠道才是这种药物真正起作用的地方,那么这个副作用就不是随机的麻烦。它恰恰紧挨着作用机制。
And now, last year, a third organ walked into the room.而现在,就在去年,第三个器官走进了这个房间。 A team led by Makoto Fukuda at Baylor College of Medicine published a paper in the journal Science Advances with a blunt title.由贝勒医学院的 Makoto Fukuda 领导的一个团队在《Science Advances》期刊上发表了一篇标题直白的论文。 Low dose metformin requires brain Rap1 for its antidiabetic action. Their claim is that the brain is not a bystander but a control room.低剂量二甲双胍的抗糖尿病作用需要脑内 Rap1。他们的论点是,大脑不是旁观者,而是控制室。 Deep in the brain sits a region called the ventromedial hypothalamus, a place that reads the body's fuel state and issues orders about it.大脑深处有一个叫做腹内侧下丘脑的区域,它读取身体的燃料状态并据此发出指令。 In that region are cells carrying a small protein called Rap1.在那个区域里有一些细胞,携带一种叫做 Rap1 的小蛋白。 When metformin reaches those cells, the team found, they fire, and blood sugar drops.该团队发现,当二甲双胍到达这些细胞时,它们就会激活,血糖随之下降。
Two of their experiments are worth picturing, because they are cleaner than most of biology. First, the dose.他们的两个实验值得想象一下,因为它们比大多数生物学实验都更干净利落。首先是剂量。 They injected metformin directly into the brains of mice, and it lowered blood sugar at amounts thousands of times smaller than a normal swallowed dose.他们把二甲双胍直接注入小鼠的大脑,结果它在仅为正常口服剂量千分之几的用量下就降低了血糖。 A few millionths of a gram did it.几百万分之一克就做到了。 Second, and this is the load-bearing one, they used mice engineered to lack that one protein, Rap1, in that one brain region.第二个实验,也是承重的那一个,他们使用了经过基因改造、在那一个脑区缺失那一种蛋白 Rap1 的小鼠。 In those mice, low dose metformin simply stopped working. Their blood sugar did not budge.在这些小鼠身上,低剂量二甲双胍干脆就不起作用了。它们的血糖纹丝不动。 But insulin still worked in them, and so did another diabetes drug. So the animals were not broken in some general way.但胰岛素在它们身上仍然有效,另一种糖尿病药物也有效。所以这些动物并不是以某种笼统的方式坏掉了。 One specific pathway had been switched off, and with it went the effect of one specific drug.有一条特定的通路被关闭了,随之消失的是一种特定药物的效果。 That is how you show a part is not merely present but necessary. You remove it and see what falls silent.这就是你如何证明一个部件不仅仅是存在,而是必需的。你把它移除,看看什么会随之沉默。
Now, there is an obvious objection, and the honest thing is to meet it head on. Metformin is famous for barely getting into the brain.现在,有一个显而易见的反驳,而诚实的做法是正面迎接它。二甲双胍以几乎进不了大脑而闻名。 So how can the brain be where it matters? The answer clears up a confusion that trips people up all the time.那么大脑怎么可能是它起作用的地方呢?答案澄清了一个长期困扰人们的误解。 Quantity is not the same as sensitivity. The brain does not need much metformin because it responds to tiny amounts.数量和敏感性不是一回事。大脑不需要多少二甲双胍,因为它对极微量就有反应。 Think of the thermostat on your wall. It is a small sensor that draws almost no power, and it controls the heating of an entire house.想想你墙上的恒温器。它是一个几乎不耗电的小传感器,却控制着整栋房子的供暖。 A little metformin reaching a very sensitive control point can, in principle, move the whole system.一点点二甲双胍到达一个非常敏感的控制点,原则上就能撬动整个系统。 So the two facts, little reaches the brain and the brain matters, can both be true at once. So what should we take from the paper?所以这两个事实——到达大脑的量很少,而大脑很重要——可以同时成立。那么我们该从这篇论文中得出什么呢?
Here is where the headlines oversold. This is a study in mice. One protein, in one brain region, at low doses.这就是那些标题夸大其词的地方。这是一项在小鼠身上做的研究。一种蛋白,一个脑区,低剂量。 The authors themselves are careful to say they are not ruling out effects elsewhere in the body at higher doses.作者自己也很谨慎地表示,他们并不排除在更高剂量下,药物在身体其他部位也有作用。 And notice what the result does not do. It does not prove the liver camp wrong, or the gut camp wrong.而且请注意这个结果没有做到什么。它并没有证明肝脏派是错的,或肠道派是错的。 It adds a third serious contender to a fight already going. The fair sentence is not we finally know how metformin works.它给一场本就在进行的争论增添了第三个严肃的竞争者。公允的说法不是我们终于知道二甲双胍是如何起作用的。 It is that at low, clinically relevant doses in mice, the brain appears to be necessary. That is a real and interesting claim.而是在小鼠身上、在低的、临床相关的剂量下,大脑看起来是必需的。这是一个真实而有趣的论断。 It is also much smaller than the headline. Step back and the deeper point comes into view.它也比标题所暗示的要小得多。退一步看,更深层的问题才浮现出来。
We have given this drug to hundreds of millions of people for more than sixty years, and there are now at least three respectable answers to where it primarily acts, each defended by a serious laboratory, each calling itself the main event.六十多年来,我们已经把这种药给了数以亿计的人,而关于它主要作用于何处,如今至少有三种站得住脚的答案,每一种都有一家严肃的实验室为之辩护,每一种都自称是主角。 It is tempting to read that as a failure. It is not. It is a fact about medicine that we mostly hide.人们很容易把这解读为一种失败。但它不是。这是医学的一个事实,只是我们大多把它藏了起来。 Drugs are approved on the question does it work and is it safe, not on the question do we understand it.药物获批依据的是它是否有效、是否安全,而不是我们是否理解它。 Aspirin was sold for about seventy years before anyone worked out what it does at the molecular level.阿司匹林卖了大约七十年,才有人搞清楚它在分子层面到底做了什么。 Lithium steadies mood, and we still argue about why. Understanding arrives after use, sometimes long after.锂能稳定情绪,而我们至今仍在争论其原因。理解总是在使用之后才到来,有时要晚很久。
That is not a scandal, but it does carry a cost.这不是什么丑闻,但它确实是有代价的。 When you do not know where a drug acts, you cannot easily predict who it will fail in, or design a cleaner version that hits only the useful target and spares the rest.当你不知道一种药作用于何处时,你就很难预测它会在谁身上失效,也很难设计出一个更干净的版本——只命中有用的靶点,放过其余。 It also matters for the newest hope pinned on metformin, that it might slow aging, now in a large trial.这对于寄托在二甲双胍身上的最新希望同样重要——它或许能减缓衰老,如今正在一项大型试验中接受检验。 Bet on an effect you cannot explain and you are betting blind.押注于一个你无法解释的效应,就是在盲目下注。 Knowing whether the true lever is in the liver, the gut, or the brain is not academic tidiness.弄清真正的杠杆在肝脏、在肠道,还是在大脑,并不是学术上的洁癖。 It is the difference between a drug we inherited and one we can improve.这是一种我们继承下来的药和一种我们能够改进的药之间的区别。
One last thought, for anyone who builds models of complicated systems. The knockout mouse is an ablation.最后一点想法,献给所有为复杂系统构建模型的人。基因敲除小鼠就是一种消融(ablation)实验。 You take a working system, remove one component, and watch whether performance collapses. If it does, that part was carrying weight.你拿一个正常运转的系统,移除其中一个组件,观察性能是否崩溃。如果崩溃了,那个部件就是在承担重量的。 If it does not, it was along for the ride.如果没有,那它不过是搭了个便车。 Same logic whether the system is a mouse or a piece of software, and one of the few clean ways to tell a part that matters from a part that merely happens to be there.无论这个系统是一只小鼠还是一段软件,逻辑都一样——这也是为数不多的、能干净利落地区分一个真正重要的部件与一个只是碰巧存在的部件的方法之一。
So the corrected, one sentence version. Metformin is not a mystery solved.所以,修正后的一句话版本是:二甲双胍并不是一个已经解开的谜。 It is a drug that worked first and is still explaining itself, and the disagreement about where it acts is not the sound of science failing.它是一种先起了作用、至今仍在为自己作解释的药,而关于它作用于何处的分歧,并不是科学失败的声音。 It is the sound of science in the middle of the question.那是科学身处问题之中的声音。
Check your understanding
Try answering before revealing — these are the points the episode turns on.
1. The brain team took mice and deleted a single protein, Rap1, in one brain region, and then low-dose metformin no longer lowered blood sugar. Why is that stronger evidence than simply showing that metformin activates those brain cells?
Showing that metformin lights up some cells only tells you the drug touches them; lots of things are touched without being load-bearing. Deleting the protein tests necessity instead of mere presence. If you remove one component and the drug's effect vanishes, that component was carrying the effect, not just going along for the ride. The design gets even more convincing because insulin and another diabetes drug still worked in the same altered mice, so the animals were not broken in some blanket way. One specific pathway was switched off, and only the drug that depends on it went silent. That is the logic of an ablation, and it is one of the few clean ways to separate a part that matters from a part that merely happens to be there.
2. Metformin is famous for barely crossing into the brain, and it piles up instead in the gut. How can the brain still be a main site of its action without contradicting that fact?
Because how much of a substance reaches a place is a different question from how sensitive that place is. The brain does not need a large dose if it responds to a tiny one, and in the mice a few millionths of a gram injected directly was enough, thousands of times less than a swallowed dose. Think of a thermostat: a small, low-power sensor that governs the heating of a whole house. So little metformin reaching the brain and the brain mattering can both be true at once. The mistake is assuming the organ that holds the most drug must be the organ where the important work happens.
3. There are now three respectable answers to where metformin acts — liver, gut, brain — each from a serious lab. Why should we read that as normal science rather than as a failure?
Because drugs are approved on whether they work and are safe, not on whether we understand them. Efficacy and safety are tested directly in trials; mechanism is a separate scientific question that often gets answered later, sometimes decades later, sometimes never in full. Aspirin was sold for about seventy years before anyone worked out what it does at the molecular level. So a live disagreement about the mechanism of a drug that plainly works is exactly what an unfinished scientific question looks like from the inside. The three camps are not evidence the field failed; they are evidence the field is still in the middle of the question, with each lab having found a real effect and each overstating how central its own effect is.
4. The headlines said we finally know how metformin works. What is the fair version of the claim the Baylor study licenses, and how do the two differ?
The fair version is narrower on several fronts. It is a study in mice, about one protein in one brain region, at low doses, and the authors themselves say they are not ruling out effects elsewhere in the body at higher doses. So the honest sentence is that at low, clinically relevant doses in mice, the brain pathway appears to be necessary. Crucially, that does not prove the liver or gut accounts wrong; it adds a third contender to an argument already underway. The gap between the headline and the claim is the difference between resolving a question and enriching it. Overstating it would repeat the pattern the episode warns about, mistaking a real but partial finding for the whole story.
5. The gut camp treats metformin's stomach side effects as a clue rather than a nuisance. Why would a side effect count as evidence about mechanism?
Because side effects tend to appear where a drug is concentrated and active. Metformin builds up in the intestine at levels far above what it reaches in the blood, and its most common early side effects are digestive. If the gut is genuinely a primary site of action, then the nausea and diarrhea are not random collateral damage happening far from the real work; they are happening right next to it. That co-location is a soft argument, not proof, but it is the kind of consistency you would expect if the mechanism and the side effect share an address. It also shows how the same fact, the drug loves the gut, feeds both a mechanistic claim and a clinical annoyance.
6. If metformin works whether or not we understand it, why does pinning down its mechanism matter in practice?
Because not knowing where a drug acts limits what you can do with it. You cannot easily predict who it will fail in, and you cannot confidently design a cleaner version that hits only the useful target and spares the tissues that produce side effects. It matters especially for the newest hope pinned on metformin, that it might slow aging, now being tested in a large trial; betting on an effect you cannot explain is betting with less information. Knowing whether the true lever sits in the liver, the gut, or the brain is the difference between a drug we inherited and stumbled into using well, and a drug we understand well enough to deliberately improve.
Further reading
- Low-dose metformin requires brain Rap1 for its antidiabetic action (Science Advances)Free, open access, technical. The primary paper from the Fukuda lab. This is where the knockout-mouse result and the microgram brain-injection doses come from; read the discussion for the authors' own caution about not excluding effects elsewhere at higher doses.
- After 60 Years, Diabetes Drug Revealed to Unexpectedly Affect The Brain (ScienceAlert)Free. A clear plain-language account of the brain finding. Useful, but note it leans toward the finally-solved framing the episode pushes back on.
- Metformin's blood sugar control starts in the brain, not just the liver, study finds (News-Medical)Free. Good on the specifics: the ventromedial hypothalamus, the SF1 neurons, and the dose comparison, and it quotes the study's own stated limitation.
- Metabolic regulation by the intestinal metformin-AMPK axis (Nature Communications)Free, open access, technical. Represents the gut camp. Read this to see that the brain paper is entering a live argument, not filling a vacuum: the intestine has its own strong claim to be a primary site of action.
- Metformin: historical overview (Diabetologia, Bailey 2017)Abstract free; full text may be paywalled depending on access. The reliable source for the goat's rue origin, Jean Sterne in 1957, and the withdrawal of phenformin and buformin for lactic acidosis. Verify the historical dates here.
- Metformin: History and mechanism of action (LGC Standards)Free. A short, readable summary of the plant origin, the biguanide family, and the frank admission that the precise molecular mechanism remains unclear after decades of use.